Champions Oncology, Inc.: Form 10-Q for the period ended Oct 31, 2019
Filed with the SEC on Dec 16, 2019 and accepted by EDGAR at Dec 16, 2019, 16:33 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-10-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2019-08-01 to 2019-10-31 | $3.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-05-01 to 2019-10-31 | $7.6m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2019-08-01 to 2019-10-31 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-05-01 to 2019-10-31 | $2.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-08-01 to 2019-10-31 | $291.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-05-01 to 2019-10-31 | −$323.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-08-01 to 2019-10-31 | $11.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-05-01 to 2019-10-31 | $26.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-08-01 to 2019-10-31 | $307.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-05-01 to 2019-10-31 | −$334.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-08-01 to 2019-10-31 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2019-05-01 to 2019-10-31 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-08-01 to 2019-10-31 | $0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-05-01 to 2019-10-31 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-08-01 to 2019-10-31 | 12,964,792 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2019-05-01 to 2019-10-31 | 11,619,569 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2019-08-01 to 2019-10-31 | $360.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Operating cash flow | 6 months2019-05-01 to 2019-10-31 | $81.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-05-01 to 2019-10-31 | $522.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-10-31 | $2.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-10-31 | $7.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-10-31 | $13.9m | us-gaap:Assets |
| Current liabilities | At period end2019-10-31 | $8.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-10-31 | $11.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-10-31 | $2.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-19-015106. Last ingested by Listed: Nov 10, 2026, 03:33 ET. Listed shows no prices and gives no investment advice.